Accrued interest

No definition available.

Name:	abvcd_AccruedInterest
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Advances bear interest description.

+ References

No definition available.

+ Details

Name:	abvcd_AdvancesBearInterestDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate working capital.

+ References

No definition available.

+ Details

Name:	abvcd_AggregateWorkingcapital
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Investment and equity transfer agreement description.

+ References

No definition available.

+ Details

Name:	abvcd_InvestmentAndEquityTransferAgreementDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	abvcd_OutstandingAdvanceFromRelatedParty
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The value of outstanding services charge.

+ References

No definition available.

+ Details

Name:	abvcd_OutstandingServicesCharge
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	abvcd_RelatedPartiesTransactionsTextualAbstract
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock purchase agreement description.

+ References

No definition available.

+ Details

Name:	abvcd_StockPurchaseAgreementDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870

+ Details

Name:	us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount receivable from related parties classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_DueFromOtherRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DueToRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Name:	us-gaap_InterestExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121576215&loc=SL77919370-209981

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121603689&loc=d3e36975-112693

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918703-209980

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121606570&loc=SL77919784-209982

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_RelatedPartyTransactionDescriptionOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShorttermDebtAverageOutstandingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=abvcd_UnsecuredConvertiblePromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_KimhoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_EuroAsiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abvcd_TypeOfCurrencyAxis=abvcd_NTMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_LbgUsaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteTaiwanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtConversionByUniqueDescriptionAxis=abvcd_ConversionAgreementsOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteBVIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_EverfrontBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_JIANGSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_LionGeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_DueToshareholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Parties Transactions (Details Textual) - USD ($)												1 Months Ended																3 Months Ended		5 Months Ended	6 Months Ended		12 Months Ended
	Jul. 01, 2020	May 08, 2020	Apr. 14, 2020	Oct. 15, 2019	Jul. 12, 2019	Jul. 02, 2019	May 12, 2019	Feb. 02, 2019	May 11, 2018	Sep. 25, 2017	Apr. 12, 2017	Feb. 18, 2020	Nov. 15, 2019	Aug. 31, 2019	Jun. 30, 2019	May 27, 2019	Feb. 27, 2019	Jan. 20, 2019	Dec. 31, 2018	Nov. 30, 2018	Sep. 30, 2018	Jun. 27, 2018	Jan. 31, 2018	Jan. 18, 2018	Dec. 31, 2017	Sep. 30, 2017	Jan. 26, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Related Parties Transactions (Textual)
Principal amount			$ 124,400
Interest expenses																												$ 140,525	$ 132,686		$ 272,042	$ 262,572
Loan maturity date			Apr. 13, 2022									Aug. 17, 2020
Conversion price														$ 7.00
Conversion of debt														$ 4,872,340
Conversion of debt, shares														696,051
Related party transactions, description																																		Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share.
Outstanding advance balance																												478,231		$ 478,231	$ 478,231		$ 425,689
Employee Stock [Member]
Related Parties Transactions (Textual)
Advances bear interest, description																															The Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of June 30, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $31,317 as of June 30, 2020. This loan bears zero interest rate and is due on demand.
Keypoint Note [Member]
Related Parties Transactions (Textual)
Principal amount																						$ 250,000
Interest rate percentage																						8.00%
Kimho [Member]
Related Parties Transactions (Textual)
Related party transactions, description						The Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of June 30, 2020 and December 31, 2019, the outstanding services charge was $52,000 and $21,500, respectively.
Outstanding advance balance																												52,000		52,000	$ 52,000		21,500
Outstanding services charge																															52,000		21,500
BioFirst [Member]
Related Parties Transactions (Textual)
Principal amount					$ 150,000
Outstanding loan balance																														64,266	128,683		128,683
Accrued interest																												17,467		17,467	$ 17,467		8,468
Loan agreement, description																															Bears interest at 1% per month (or equivalent to 12% per annum
Aggregate working capital					21,317
Stock purchase agreement, description										On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.
Outstanding advance balance																												64,266		64,266	$ 64,266		24,182
Rgene Corporation [Member]
Related Parties Transactions (Textual)
Principal amount																												39,233		39,233	39,233		36,332
Outstanding loan balance																															31,711		29,194
Accrued interest																												7,522		7,522	$ 7,522		7,138
Loan agreement, description																															The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019
Euro Asia [Member]
Related Parties Transactions (Textual)
Outstanding advance																												30,000		30,000	$ 30,000		12,000
Outstanding advance balance																												30,000		30,000	30,000		12,000
Asiangene Corporation [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																															3,397		3,340
Accrued interest																												450		450	450		238
Aggregate working capital																																		$ 24,017
Amount of equivalent																$ 3,400
Interest rate percentage																																		0.00%
Outstanding advance balance																												24,017		24,017	24,017		24,017
Asiangene Corporation [Member] \| NT [Member]
Related Parties Transactions (Textual)
Loan agreement, description																The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019.
Aggregate working capital																$ 100,000
BioFirst (Australia) [Member]
Related Parties Transactions (Textual)
Principal amount					$ 150,000				$ 40,000
Outstanding loan balance																															$ 361,487		40,000
Interest rate percentage					12.00%				0.00%																						12.00%
Loan maturity date					Dec. 31, 2019
Other receivable from related parties																												118,029		118,029	$ 118,029		115,946
Advances bear interest, description					The advances bear interest 1% per month
BioFirst (Australia) [Member] \| Subsequent Event [Member]
Related Parties Transactions (Textual)
Principal amount	$ 321,487
Interest rate percentage	12.00%
Loan maturity date	Jun. 30, 2021
LBG USA, Inc.[Member]
Related Parties Transactions (Textual)
Loan agreement, description																	The advances bear 0% interest rate and are due on demand.
Outstanding advance																			$ 0									675		675	$ 675		675	$ 0
BioLite Taiwan [Member]
Related Parties Transactions (Textual)
Loan agreement, description																															The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.
Aggregate working capital																				$ 430,817
Interest rate percentage																				0.00%
Other receivable from related parties																			$ 0															$ 0
Conversion price																				$ 7.00
Conversion of debt																				$ 428,099
Conversion of debt, shares																				61,157
BioLite Taiwan [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital																				$ 13,295,000
BioFirst [Member]
Related Parties Transactions (Textual)
Aggregate working capital																									$ 625,646		$ 950,000
Interest rate percentage								12.00%																	12.00%						12.00%
Loan maturity date								Feb. 01, 2020																	May 27, 2020
Conversion price																									$ 7.00
Conversion of debt																									$ 625,646
Conversion of debt, shares																									89,378
Stock purchase agreement, description								On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company’s common stock at a conversion price of $7.00 per share.							Pursuant to which the Company agreed to issue 428,571 shares of the Company’s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.
BioFirst [Member] \| Conversion Agreements One [Member]
Related Parties Transactions (Textual)
Interest rate percentage																									0.00%
Stock purchase agreement, description																									On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company’s common stock at a conversion price of $7.00 per share.
BioFirst [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital																									$ 19,430,000
BioLite BVI [Member]
Related Parties Transactions (Textual)
Aggregate working capital											$ 987,134
Interest rate percentage											12.00%
Loan maturity date							May 11, 2020				May 11, 2019
Stock purchase agreement, description							On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company’s common stock at a conversion price of $7.00 per share.
BioLite BVI [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital											$ 30,000,000
Everfront Biotech Inc. [Member]
Related Parties Transactions (Textual)
Investment and equity transfer agreement, description																										Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.
YuanGene [Member]
Related Parties Transactions (Textual)
Aggregate working capital																							$ 42,690	$ 50,000							$ 9,205
Interest rate percentage																							0.00%	12.00%							0.00%
Loan maturity date																		Jan. 19, 2020						Jan. 19, 2019
Conversion price																		$ 7.00					$ 7.00
Conversion of debt																		$ 50,000					$ 42,690
Conversion of debt, shares																		7,143					6,099
Related party transactions, description																							On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company’s common stock at a conversion price of $7.00 per share.
Outstanding advance balance																												0		0	$ 0
Jiangs [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																															10,190		10,030
Accrued interest																												768		768	768		154
Interest expenses																												306	0		$ 600	0
Loan agreement, description																															The advances bear 0% interest rate and are due on demand.
Aggregate working capital																															$ 15,073
Interest rate percentage																			0.00%
Related party transactions, description																																		Since 2018, the Jiangs have advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company’s common stock at a conversion price of $7.00 per share.
Jiangs [Member] \| NT [Member]
Related Parties Transactions (Textual)
Loan agreement, description													The advances bear 1% interest rate per month.
Aggregate working capital													$ 300,000
Amount of equivalent													$ 10,190
Lion Gene [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																															10,190		10,030
Accrued interest																												882		882	882		255
Interest expenses																												306	0		600	0
Lion Gene [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital				$ 300,000
Amount of equivalent				$ 10,190
Due to shareholders [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																															158,288		155,800
Accrued interest																												194		194	194		0
Interest expenses																												6,003	$ 5,730		12,006	$ 11,460
Outstanding advance balance																												189,952		189,952	189,952		284,479
Due to shareholders [Member] \| NT [Member]
Related Parties Transactions (Textual)
Loan agreement, description																					The advances bear 13.6224% interest rate per annum.
Aggregate working capital																					$ 4,660,000
Amount of equivalent																					$ 150,052
BioLite Japan [Member]
Related Parties Transactions (Textual)
Loan agreement, description		The Company advanced an amount of $100,000 and the advance bear 0% interest rate.
Aggregate working capital		$ 150,000
Outstanding advance																												$ 100,000		$ 100,000	$ 100,000		$ 0